ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

ENDRA Life Sciences Inc. , a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound , announces that the Company's De Novo request for the TAEUS liver system has advanced to...

Related Keywords

Francois Michelon ,Endra Life Sciences Inc ,Drug Administration ,Life Sciences ,Securities Exchange ,Exchange Commission ,Company De Novo ,Life Sciences Inc ,Sciences Inc ,Thermo Acoustic Enhanced Ultrasound ,Non Alcoholic Fatty Liver Disease ,Chief Executive Officer Francois ,Submission Template And Resource ,Steatotic Liver Disease ,Securities Act ,Securities Exchange Act ,Risk Factors ,Financial Condition ,Annual Report ,Quarterly Reports ,Markets ,